Core Insights - The stock price of Via Biotechnology (01873) increased by 11.32% on August 14, reaching HKD 2.36 per share with a trading volume of HKD 30.83 million [1] - Via Biotechnology provides comprehensive drug development services from research to commercialization for global innovative pharmaceutical companies, including CRO services and CMC/CDMO solutions [1] - As of December 31, 2023, Via Biotechnology has served a total of 2,278 biotech and pharmaceutical clients and incubated 92 biotech startups [1] Financial Performance - For the fiscal year ending 2024, Via Biotechnology reported total revenue of RMB 1.987 billion and a net profit of RMB 167 million [2]